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Introduction
Drug delivery to the central nervous system (CNS) has been a considerable challenge in biomedical research in the past decades. [1, 2] Neurological disorders such as Alzheimer's and Parkinson's diseases, stroke, multiple sclerosis and also neurotraumatic conditions, such as spinal cord injury (SCI), are amongst the main debilitating disorders of our times. [3] The unique environment and the complexity of the mechanisms involved in these conditions, some of which still poorly understood, have hindered the development of new and efficient treatments. The systemic administration of neuroactive molecules poses several intrinsic issues, particularly its toxicity and reduced stability in the organism. [4] Thus, there is an urgent demand not only for more detailed knowledge of the pathophysiology of CNS disorders, but also for more specific and effective drug delivery strategies. [5, 6] Another major issue for drug delivery in the CNS is the presence of biological barriers such as the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) that can obstruct the entry of therapeutic molecules to the nervous tissues. [7, 8] Nonetheless, one must distinguish diseases that do not affect the BBB integrity from those which compromise it. [9] In the first case, the major obstacle to an effective cure of the disease is the BBB presence itself and its characteristics. However, when this barrier has been compromised, for instance, after neurotraumatic events, the delivery of compounds is clearly eased. [10] In brain and SCI physical damage occurs and the CNS barriers are disrupted opening a 'window of opportunity' for the entry of drugs that can limit the extent of following potential secondary damage. [10, 11] Still, efficient drug delivery to the target cells remains a crucial task for the success of these therapies, since most of these drugs are often highly unspecific. [12] The use of nanoparticle-based systems has gained increasing interest in drug delivery with exciting prospects. [13] These nanoscale materials present unique and advantageous features in comparison to the classical drug formulations, regarding its solubility, biodistribution, release characteristics and immunogenicity. [14] In addition, nanoparticles are amenable to further modifications that can provide higher functionalization degrees, namely cell or tissue targeting. [13] Fundamentally, nanoparticlemediated selective drug delivery would offer a mean to minimize delivery to unintended sites, allowing higher doses of drug to be administered when reaching a precise target site, thereby lowering peripheral cytoxicity. A critical step in such a strategy is the internalization of nanoparticles into specific cells, and a way to overcome it would be the modification of the nanoparticle surface with a ligand, that would be efficiently taken up by target cells. [15, 16] A vast range of nanoparticles is being developed and investigated for specific drug delivery purposes although from these only a small percentage is being directed to CNS. [17, 18] A new surface engineered macromolecular carrier was recently proposed to be used in CNS applications, showing high internalization levels and no significant cytotoxicity over neurons and glial cells. [19] Moreover, it has also shown to be non-cytotoxic in vivo, revealing a wide biodistribution after intravenous injections, being simultaneously able to cross the BCSFB. [20] This system was firstly described as a new surface engineered nanoparticle based on a polyamidoamine (PAMAM) dendrimer core grafted with the natural polymer carboxymethylchitosan (CMCht). [21] The sphere-like CMCht/PAMAM dendrimer nanoparticles were proposed to be used as targeted drug delivery carriers for the modulation of the cells' behaviour by efficient intracellular uptake upon its functionalization via: (i) drug incorporation; (ii) fluorescent labelling and (iii) ligand conjugation. [22] Furthermore, an anti-inflammatory corticosteroid clinically used in SCI related cases-methylprednisolone (MP)-has already shown to be efficiently incorporated and released from these nanoparticles, leading to important alterations on the viability of primary cultures of microglial cells. [23] Therefore, following recent developments of these previous works the aim of this study was to achieve a higher functionalization level of the CMCht/PAMAM dendrimer nanoparticles by conjugating to the latter a targeting ligand, in order to determine a possible modulation of their internalization behaviour in glial cells. From the variety of potential ligands to nanoparticles surfaces, monoclonal antibodies are attractive molecules due its high specificity. [24] Therefore, the MP-loaded CMCht/PAMAM dendrimer nanoparticles were conjugated to the CD11b antibody which recognizes specific receptors on microglial cells' membranes. [21] Starburst PAMAM-carboxylic acid terminated dendrimer solution (PAMAM-CT) (generation 1.5, 20% w/v) was purchased (Sigma, Germany). The following reactions were carried out: (i) increase in the PAMAM-CT generation; (ii) production of a PAMAM-methyl ester terminated dendrimer; (iii) condensation reaction between the methyl ester and amine groups of PAMAM and CMCht and (iv) conversion of the non-reacting methyl ester groups into carboxylic ones in the CMCht/PAMAM dendrimer nanoparticles. Initially, the methanol was removed from the PAMAM-CT dendrimers by evaporation under nitrogen gas. The remaining compound was re-dissolved in ultra-pure water in a final concentration of 10 mg Á mL À1 and the pH was corrected to 6.5.
Then, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC, Fluka, Slovakia) was added under agitation for 30 min at room temperature. Ethylenediamine (EDA, Sigma, Germany) was included at the same molar ratio and reacted for 4 h. The solution was subsequently dialysed against ultrapure water in order to remove the exceeding EDC (cellulose tubing, benzoylated for separating compounds with a molecular weight of 1 200, Sigma, Germany). The obtained amine terminated PAMAM dendrimers (PAMAM-AT) were mixed with methanol (Sigma, Germany) and methyl methacrylate (Fluka, Germany) and kept under agitation in a water bath at 50 8C for 24 h. After methanol removal under nitrogen gas, appropriate volumes of hydrochloric acid (HCl, Panreac, Portugal) and trifluoroacetic acid (TFA, Sigma, Germany) were added to the solution. Meanwhile, 1 g of CMCht was dissolved in 50 mL of water. The PAMAM methyl ester terminated dendrimers were dissolved in a 20:80 water/methanol solution and the CMCht was added and kept under agitation for 72 h, after which the CMCht/PAMAM dendrimer nanoparticles with carboxylicterminated groups were obtained. 
Methylprednisolone Incorporation into the

CD11b Antibody Conjugation to CMCht/PAMAM Dendrimer Nanoparticles
In order to conjugate anti-mouse CD11b antibody (BD Biosciences, USA) to the dendrimer nanoparticles a crosslinking reaction was performed (Scheme 1). [25] A 20 mg Á mL À1 solution of nanoparticles in phosphate buffer saline (PBS) was mixed with 1 mg Á mL À1 EDC (Fluka, Slovakia) and let react for 30 min. The remaining solution was dialysed against ultrapure water for 24 h to remove the excess EDC. Afterwards, the pH was corrected to 7.4 and 4 nmol of CD11b antibody were added under agitation. One hour after CD11b addition, the solution was frozen at À80 8C and subsequently freeze-dried (Telstar-Cryodos-80, Spain).
Characterization of the CD11b Antibody Conjugated Dendrimer Nanoparticles
The conjugation effectiveness was analysed by FTIR spectroscopy and 1 H NMR. The morphology of the new conjugated nanoparticles was assessed by scanning-transmission electron micro- 
Establishment of Rat Cortical Microglial Cells
After the glial cells isolation procedure, these were plated out at a density of 1 Â 10 6 cells Á cm À2 in polystyrene T75 flasks (Thermo Scientific, USA) previously coated with poly-L-lysine (Sigma, USA). The glial primary cultures were maintained at 37 8C in a 5% CO 2 atmosphere in DMEM (Gibco, USA) supplemented with 10% FBS and 1% antibiotic/antimycotic for 2 weeks, with periodical medium renewal. After that, the flasks were agitated in an orbital shaker at 240 rpm during 4 h. Following this, the medium containing detached microglia cells was collected and the obtained suspension was centrifuged at 1 200 rpm for 5 min. The pellet was re-suspended in DMEM medium (Gibco, USA) supplemented with 10% FBS and 1% antibiotic/antimycotic and plated out at a density of 4 Â 10 4 cells Á cm À2 on coverslips previously coated with poly-Llysine (Sigma, USA). Microglia cells primary cultures were then maintained at 37 8C in a 5% CO 2 atmosphere, in DMEM medium (Gibco, USA) supplemented with 10% FBS and 1% antibiotic/ antimycotic for 4 d for further testing.
In vitro Cytotoxicity Assays
Unmodified and CD11b antibody-conjugated MP-loaded CMCht/ PAMAM dendrimer nanoparticles were evaluated regarding its influence in the primary cell cultures' viability. For that purpose, two concentrations of nanoparticles were tested: 200 and 400 mg Á mL
À1
and the cultures were exposed to these conditions for a week. For both glial and microglial cell cultures the cell viability was verified after incubation of the cells at 37 8C for 3 h with (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulphophenyl)-2H tetrazolium) (MTS, Promega, USA) in a 5:1 ratio. This compound is bioreduced by active dehydrogenase enzymes into a brown formazan product that is released to the medium. After the incubation, the optical density of each sample was read in a multiplate reader (Tecan Sunrise, Switzerland) at 490 nm.
Internalization Assessment by Immunocytochemistry
After a week, the glial cultures were incubated with 200 mg Á mL Thermo Scientific, USA, 1:2 000), for 5 min in the dark. The coverslips were finally mounted for posterior observation under an Olympus BX-61 Fluorescence Microscope (Olympus, Germany). The FITClabelled dendrimer nanoparticles internalization levels for each cell population were determined according to Equation (1) (n ¼ 3, 3 random fields/coverslip):
I is the percentage of internalization, P c the number of positive cells for FITC-labelled dendrimer nanoparticles and T c is the total number of each cell type.
Statistical Analysis
Statistical evaluation was performed using the one-way analysis of variance test followed by the Tukey's post-test to assess the statistical differences between groups in the viability and internalization tests. Statistical significance was defined for p < 0.05.
Results and Discussion
The partial failure in CNS disorders' pharmacological treatments often resides in the lack of targeting of the administered therapeutic molecules. [4] Even in conditions where the BBB has been compromised and the delivery of compounds is considerably facilitated, as in SCI, efficient drug delivery to target cells should be carefully considered. Due to the massive inflammatory episodes that follow these injuries, a cell-specific drug delivery could be highly advantageous in the control and modulation of these deleterious events. [9] For instance, MP clinical administration as an antiinflammatory drug aggravates a cascade of side effects that could be minimized in a targeted delivery strategy. [27] Following previous works by our group focusing on the development of a CNS targeted dendrimer-based macromolecular carrier, [19, 20, 23] we aimed at further modifying the CMCht/PAMAM dendrimer nanoparticles to achieve a higher functionalization degree. [28] For this purpose, we tested a new surface modification by conjugating a CD11b antibody to the MP-loaded CMCht/ PAMAM dendrimer nanoparticles. The latter had already shown to be easily internalized by astrocytes, oligodendrocytes and microglial cells present in a mixed primary culture. All these cell types revealed maximum internalization levels 24 h after exposure to these nanoparticles, being microglial cells the ones with faster uptakes. [23] If we intend to target the delivery of the drug to microglial cells, for instance, minimum amounts should reach the other cell types in order to maximize the desired drug actions while minimizing possible side effects. Therefore, it was investigated whether this generalized internalization intake would be affected by the presence of CD11b antibody, which is specific for microglial cell recognition. The CD11b antibody was chosen to facilitate the permeation of the nanoparticles through the microglial cells membrane by specifically interacting with an integrin chain expressed only in this type of cells. In this way, the nanoparticles could still be targeted to microglial cells, but its entrance in the other cell types would be compromised. In the present study, it was initially investigated the conjugation of the CD11b antibody to the CMCht/PAMAM dendrimer nanoparticles. FTIR spectra of the unmodified and antibody-conjugated CMCht/PAMAM dendrimer nanoparticles are represented in Figure 1A . From Figure 1 , it is visible that the antibody-conjugated nanoparticles disclose an altered FTIR spectrum as compared to the unmodified nanoparticles. The 520 cm À1 free amino acid peak and the 1 120 cm À1 NH þ 3 vibration appear after modification of the nanoparticles in the antibodyconjugated nanoparticles spectrum. Consequently, the comparative FTIR spectra analysis of the unmodified and CD11b conjugated dendrimer nanoparticles seems to suggest that the antibody was, in fact, successfully conjugated to the nanoparticles. Also the 1 H NMR spectra of CD11b antibody-conjugated and unmodified CMCht/ PAMAM dendrimer nanoparticles ( Figure 1B) revealed new proton signals which indicate that the conjugation actually occurred. Some characteristic peaks of the CMCht/PAMAM dendrimer nanoparticles are maintained in both spectra, such as the 2.17 ppm CH 2 protons from the PAMAM dendrimer and the 4.07 ppm CH 2 COO -protons from CMCht.
Also new signals were observed at 1.26 ppm and 2.71 ppm which are attributed to new COCH 3 and NCH 3 protons from the newly formed bonds. These new signals strongly suggest that the conjugation of CD11b antibody to the nanoparticles actually occurred. Additionally, STEM analysis ( Figure 1C ) also confirmed the spheric morphology of these nanoparticles. Regarding the biological assays, both the glial and microglial cell cultures were incubated with two different concentrations of the CD11b-conjugated and the unmodified MP-loaded CMCht/PAMAM dendrimer nanoparticles. The metabolic activity was then quantified by means of performing an MTS assay. In all the tested conditions no negative effect in the normal cell activity was observed (Figure 2 ). Both cell populations reduced detectable amounts of MTS in similar ways to those of control cultures, showing normal cell viability and metabolism. Only a slight, but significant, increase in the metabolic activity of glial cells after 200 mg addition of CD11b-conjugated MPloaded CMCht/PAMAM dendrimer nanoparticles was observed. These data suggest that there is no cytotoxicity derived from the exposure of these cells to the multifunctionalized nanoparticles.
The internalization of the nanoparticles by each cell type in the mixed primary culture of glial cells was then further investigated. To allow both a qualitative and a quantitative evaluation, cells were immunostained for observation and the number of cells containing fluorescently labelled internalized nanoparticles was determined. A previous study has shown that microglial cells presented maximum MP-loaded CMCht/PAMAM dendrimer nanoparticles internalization levels, with all cells evidencing nanoparticles within its cytoplasmic compartment 24 h after nanoparticles addition. [23] Moreover, astrocytes also reached high internalization levels around 90% followed by oligodendrocytes, which presented a slightly lower percentage of nanoparticles internalizing cells (around 80%). As observed in Figure 3 , the CD11b conjugation to the MP-loaded CMCht/PAMAM dendrimer nanoparticles did not alter the percentage of microglial cells internalizing the nanoparticles as compared to cultures exposed to MP-loaded CMCht/ PAMAM dendrimer nanoparticles. Importantly, however, this was not true for the other glial cell types. Regarding astrocytes, a drastic and significant decrease in the antibody-conjugated nanoparticles uptake was observed (around 50%), as seen in Figure 3 . Similar to what it was observed in astrocytes, oligodendrocytes also revealed a significant decrease regarding the CD11b-conjugated MPloaded CMCht/PAMAM dendrimer nanoparticles uptake. Again, the number of oligodendrocytes internalizing the modified nanoparticles was drastically reduced to 40% when compared to the unmodified nanoparticles condition. The endocytosis pathway is believed to be the major route for dendrimer nanoparticles internalization, [21, 29] and it was already shown that surface modifications modulate this mechanism. [30] Thus, our strategy to modify the nanoparticles with an antibody that is efficiently taken up by microglial cells via receptor-mediated endocytosis seems to be advantageous in diminishing the non-specific uptake modulation by other cell types, such as astrocytes and oligodendrocytes. The yield of nanoparticles internalization by microglial cells did not improve, since maximum percentage figures were already being reached. However, the receptor-mediated endocytosis facilitation to microglial cells, due to the interaction of CD11b antibody-conjugated nanoparticles, indeed contributed to the improvement of their intracellular uptake and conferred a targeted profile to the system, drastically reducing the uptake by astrocytes and oligodendrocytes.
Thus, we demonstrate that the CD11b antibodyconjugated MP-loaded CMCht/PAMAM dendrimer nanoparticles can be beneficial when envisioning the development of targeted therapies aimed at applications in CNS disorders, namely by carrying anti-inflammatory drugs such as MP to inflammation mediator cells.
Conclusion
Within the present study it was possible to describe for the first time the successful functionalization of MP-loaded CMCht/PAMAM dendrimer nanoparticles with a microgliaspecific antibody, acting as a targeting ligand. The new sphere-like CD11b antibody-conjugated nanoparticles revealed no cytotoxicity when added to glial and microglial primary cell cultures. Furthermore, a novel nanoparticle uptake profile by astrocytes and oligodendrocytes was achieved with the new modified nanoparticles. These cells significantly reduced the levels of CD11b antibody-conjugated nanoparticles internalization, while maintaining maximum uptake by microglial cells. Further studies will focus on the potential selective anti-inflammatory action of these nanoparticles, namely for SCI applications.
